European Commission approves Cyramza (ramucirumab)for indications in NSCLC and colorectal cancer-Eli Lilly
Eli Lilly and Company announced that the European Commission has approved Cyramza (ramucirumab) for two new indications : 1. in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non small lung cancer (NSCLC) with disease progression after platinum based chemotherapy and 2. in combination with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) for treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with Avastin (bevacizumab), oxiplatin and a fluoropyrimidine.
Comment: With this approval ramucirumab is the first EU medicine approved for use in combination with docetaxel in pre-treated patients with NSCLC regardless of histology.
Comment:Clinical data from the REVEL trial showed that the drug, given alongside docetaxel, helped extend survival by an average of 1.4 months in around half of the NSCLC patients treated with the combination, compared to half of those docetaxel plus a placebo. This trial included squamous (73%) and non squamous (23%) forms of NSCLC.
Comment: Colorectal cancer patients treated with the Cyramza plus FOLFIRI regimen in the RAISE trial achieved a median overall survival of 13.3 months versus those given placebo plus FOLFIRI who achieved 11.7 months, which has reduced the risk of patient death by 15%.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)